In the published article, there was an omission in Materials and Methods. Anti GAPDH monoclonal antibody 14C10 was used as loading control in experiments presented in Figures 3, 5. The correct materials and methods paragraph appears below.
Figure 3
Figure 5
2 Materials and Methods
2.1 Chemicals
Chemicals were of analytical or tissue culture grade and purchased from Sigma-Aldrich (St. Louis, MO, USA). Molecular biology and electrophoresis reagents were from Thermo-Fisher Scientific (Carlsbad, CA, USA) or BioRad (Hercules, CA, USA). The following antibodies were used: anti FXYD5/Dys: a) D-2 (mouse monoclonal) and b) FL-178 (rabbit polyclonal) from Santa Cruz Biotechnology (SCBT; Santa Cruz, CA, USA); anti E-cadherin 610181 (mouse monoclonal; Becton Dickinson Biosciences, BD; San Diego, CA, USA); anti NF-κB p65 (rabbit monoclonal; C22B4, Cell Signaling, Danvers, MA, USA); anti phospho-NF-κB p65 (Ser536) (rabbit monoclonal; 93H1, Cell Signaling); anti IκB-α (rabbit polyclonal; #9242, Cell Signaling); anti β-Tubulin (mouse monoclonal; clone D66, Sigma-Aldrich); anti GAPDH (rabbit monoclonal; clone 14C10, Cell Signaling). Cy3-labelled anti-mouse or anti-rabbit secondary antibodies (Sigma-Aldrich) were used for immunocytochemistry. Horseradish peroxidase-conjugated anti-mouse (Vector Laboratories Inc., Burlingame, CA, USA) or anti-rabbit (Sigma-Aldrich) IgG were used as secondary antibodies in Western immunoblotting assays.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
In the published article, there was an error in Figure 3. Modulation of FXYD5/Dys expression in Hec1a cells and changes in cell migration, and in Figure 5. FXYD5/Dys expression and NF-κB pathway activation. In both cases, it was indicated that “β-Tubulin (anti β-Tubulin monoclonal antibody D66; 0.5 µg/mL) was used as loading control”. This is a mistake, since in both cases anti GAPDH monoclonal antibody 14C10 was used as loading control.
The corrected Figure 3 and Figure 5 and their legends appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
endometrial cancer, E-cadherin, FXYD5, dysadherin, TGF-β1, NF-κB, CCL-2
Citation
Besso MJ, Rosso M, Lapyckyj L, Moiola CP, Matos ML, Mercogliano MF, Schillaci R, Reventos J, Colas E, Gil-Moreno A, Wernicke A, Orti R and Vazquez-Levin MH (2024) Corrigendum: FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways. Front. Oncol. 13:1322204. doi: 10.3389/fonc.2023.1322204
Received
18 October 2023
Accepted
22 December 2023
Published
23 January 2024
Volume
13 - 2023
Edited and reviewed by
Tao Liu, University of New South Wales, Australia
Updates
Copyright
© 2024 Besso, Rosso, Lapyckyj, Moiola, Matos, Mercogliano, Schillaci, Reventos, Colas, Gil-Moreno, Wernicke, Orti and Vazquez-Levin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mónica Hebe Vazquez-Levin, mhvazquez@ibyme.conicet.gov.ar; mhvazl@gmail.com
†Present address: Jaume Reventos, Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.